Find a Clinical Trial

Find a Clinical Trial

Search by practice name, trial titles, indicators and specific disease types.

Gall Bladder Cancer

Clinical Trial at: Arizona Oncology - Tucson

A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)

  • Details

ClinicalTrials.gov ID: NCT03773302
Diagnosis Type: Gall Bladder Cancer
USOR Number: 18264

  • Practice Details

1845 W. Orange Grove, Bldg. 2
Tucson, AZ 85704
P: (520) 624-7445

More Details View Practice Page

Gall Bladder Cancer

Clinical Trial at: Arizona Oncology - Tucson

A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)

  • Details

ClinicalTrials.gov ID: NCT03773302
Diagnosis Type: Gall Bladder Cancer
USOR Number: 18264

  • Practice Details

2070 W. Rudasill Rd., #130
Tucson, AZ 85704
P: (520) 797-4468

More Details View Practice Page

Gall Bladder Cancer

Clinical Trial at: Arizona Oncology - Tucson

A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)

  • Details

ClinicalTrials.gov ID: NCT03773302
Diagnosis Type: Gall Bladder Cancer
USOR Number: 18264

  • Practice Details

603 N Wilmot Rd, Suite 151
Tucson, AZ 85711
P: (520) 886-0206

More Details View Practice Page

Gall Bladder Cancer

Clinical Trial at: Texas Oncology - Tyler

A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)

  • Details

ClinicalTrials.gov ID: NCT03773302
Diagnosis Type: Gall Bladder Cancer
USOR Number: 18264

  • Practice Details

910 E Houston St, Suite 100
Tyler, TX 75702
P: (903) 579-9800

More Details View Practice Page

Gall Bladder Cancer

Clinical Trial at: Compass Oncology - Vancouver

A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)

  • Details

ClinicalTrials.gov ID: NCT03773302
Diagnosis Type: Gall Bladder Cancer
USOR Number: 18264

  • Practice Details

210 SE 136th Ave
Vancouver, WA 98684
P: (360) 944-9889

More Details View Practice Page

Gall Bladder Cancer

Clinical Trial at: Virginia Oncology Associates - Virginia Beach

A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)

  • Details

ClinicalTrials.gov ID: NCT03773302
Diagnosis Type: Gall Bladder Cancer
USOR Number: 18264

  • Practice Details

1950 Glenn Mitchell Dr, Suite 102
Virginia Beach, VA 23456
P: (757) 368-0437

More Details View Practice Page

Gall Bladder Cancer

Clinical Trial at: Texas Oncology - Waco

A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)

  • Details

ClinicalTrials.gov ID: NCT03773302
Diagnosis Type: Gall Bladder Cancer
USOR Number: 18264

  • Practice Details

6520 Horizon Circle
Waco, TX 76712
P: (254) 755-4460

More Details View Practice Page